Therapeutic Asset Ratings

210 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Lorlatinib Glioblastoma	Nationwide Children's Hospital	Early P1	C (34)
Panitumumab-Irdye800 Glioblastoma	Eben Rosenthal	Early P1	C (34)
Posaconazole Glioblastoma	Milton S. Hershey Medical Center	Early P1	C (34)
Senicapoc Glioblastoma	Aarhus University Hospital	Early P1	C (34)
Zimberelimab Glioblastoma	Yale University	Early P1	C (34)
BLOOD, WHOLE Glioblastoma	Centre Leon Berard	N/A	D (28)
Personalized Dendritic Cell Vaccine Zsneo-Dc1.1 Glioblastoma	ZSky Biotech Inc	P2	NR (0)
cm93 Glioblastoma	Crimson Biopharm Inc.	P1	NR (0)
Pep-Cmv Vaccine Glioblastoma	Charlotte Lemech	P1	NR (0)
Survivin-Loaded Dendritic Cell Glioblastoma	Beijing Tricision Biotherapeutics Inc	P1	NR (0)

Showing 201 to 210 of 210 assets

PreviousPage 9 of 9Next